Bioverge Monthly — July 2017
Introduction
Bioverge is a virtual venture capital firm and curated marketplace helping investors identify, fund, and support promising life sciences and healthcare technology startups.
Why Us?
Our Digital Marketplace
Our mission is to democratize early stage investing in the $2 trillion healthcare market, while offering founders access to capital and an ecosystem of resources to help them push the boundaries of human healthcare.
Our goal is to build awareness of innovative investment opportunities and provide investors the tools and resources necessary to make informed investment decisions. To accomplish this goal, we’ve set out to build a high quality, curated healthcare-dedicated digital marketplace.Read More
Portfolio Updates
Notable Labs’ CEO Matt De Silva and his team at Notable Labs reveal the storybehind their mission to provide individualized cancer therapy using the Echo Acoustic Liquid Handling technology.
CrowdMed To date, CrowdMed has resolved over 2,000 real-world complex medical cases, with a 77% success rate producing a medically confirmed diagnosis. These patients had been sick for an average of 7.2 years before coming to CrowdMed, seen an average of 8.4 physicians, and incurred an average of $65,000 in medical costs. CrowdMed’s patients prefer the platform 4.4x times over the traditional medical system and credit the company with reducing their medical costs by 27% going forward on average.
Echo Labs’ CEO Eugene Cho explains how marketing and branding were key to their early success and how they affected the company’s valuation: “What we didn’t expect was that there would be lines and word would get out and people would tweet about this, and at the show we would very quickly run out of these wooden scopes.”
A Few of Our Favorite Stories
The Gene Editors Are Only Getting Started (WSJ). Would you eradicate malaria-carrying insects? Change your baby’s DNA? Scientists soon may have the power to do both
New Natural Selection: How Scientists are Altering DNA to Genetically Engineer New Forms of Life (Newsweek). Scientists are altering our genetic code and engineering new forms of material that improve nature, from flowers that can detect bombs to bacteria that secretes fuel.
Silicon Valley’s biggest start-up factory is making a bet on biotech, but it’s not an obvious fit (CNBC). Silicon Valley’s best known startup accelerator, Y Combinator, thinks it has found a new type of biotech startup.
Cancer Cures, Gene Therapy, Pig Transplants, And More: 10 Early-Stage Biotech Startups To Watch (CB Insights). Startups are applying innovative techniques to cure the common cold, re-engineer the human microbiome, and fight against cancer.
Stanford computer scientists develop an algorithm that diagnoses heart arrhythmias with cardiologist-level accuracy (Stanford News). A new deep learning algorithm can diagnose 14 types of heart rhythm defects, called arrhythmias, better than cardiologists. This could speed diagnosis and improve treatment for people in rural locations.

Join Our Community
Sign up today if you’re ready to invest in healthcare startups transforming tomorrow. Please support us as we continue to grow our presence and join our AngelList Syndicate and follow us on Twitter, LinkedIn, and Facebook.
-The Bioverge Team
- Sign up for our monthly newsletter
- Access our deal flow: Investors sign up for free!
- Are you a health-tech company raising a Seed or Series A? Apply to raise capital
- Follow us on Medium Bioverge
- Follow us on Twitter @biovergehq
